DigitalOcean Holdings, Inc. (DOCN) Q3 Earnings and Revenues Top Estimates — Positive
DOCN Zacks Investment Research — November 05, 2025DigitalOcean Holdings, Inc. (DOCN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.52 per share a year ago.
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates — Negative
EYPT Zacks Investment Research — November 05, 2025EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.54 per share a year ago.
Bentley Systems, Incorporated (BSY) Matches Q3 Earnings Estimates — Positive
BSY Zacks Investment Research — November 05, 2025Bentley Systems, Incorporated (BSY) came out with quarterly earnings of $0.27 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
Fidelity National Information Services (FIS) Q3 Earnings and Revenues Beat Estimates — Positive
FIS Zacks Investment Research — November 05, 2025Fidelity National Information Services (FIS) came out with quarterly earnings of $1.51 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.4 per share a year ago.
OPENLANE (KAR) Q3 Earnings and Revenues Surpass Estimates — Positive
KAR Zacks Investment Research — November 05, 2025OPENLANE (KAR) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.26 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates — Neutral
FHTX Zacks Investment Research — November 05, 2025Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates — Negative
XFOR Zacks Investment Research — November 05, 2025X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $5.41 per share a year ago.
New York Times Co. (NYT) Beats Q3 Earnings and Revenue Estimates — Positive
NYT Zacks Investment Research — November 05, 2025New York Times Co. (NYT) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.45 per share a year ago.
As Nvidia (NASDAQ: NVDA) stock faces short-term bearish price movement, an artificial intelligence (AI) model is projecting the equity is likely to trade above $200 by the end of November.
UTime Limited Actively Expands Global Smart Wearable Device Market — Neutral
WTO GlobeNewsWire — November 05, 2025SHENZHEN, China, Nov. 05, 2025 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO) today announced that it is actively promoting its smart wearable devices to more international markets through its existing global distribution channels and partner network.
Terreno Realty Corporation Adds Independent Director — Neutral
TRNO Business Wire — November 05, 2025BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation Adds Independent Director.
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 — Neutral
PCSA GlobeNewsWire — November 05, 2025VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 (499) in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, has been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9, 2025, in Houston, Texas.
Teva Pharmaceuticals stock surges 12% as branded drug sales outperform — Positive
TEVA Invezz — November 05, 2025Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio.
HIDDEN VALLEY RANCH® TURNS TINY NYC APARTMENT INTO THE ULTIMATE POP-UP RESTAURANT EXPERIENCE — Neutral
CLX PRNewsWire — November 05, 2025The Brand's First-Ever Pop-Up Restaurant Proves that with Hidden Valley Ranch Seasoning, Big Kitchens Aren't Necessary to Cook Like a Pro OAKLAND, Calif. , Nov. 5, 2025 /PRNewswire/ -- Hidden Valley® Ranch, the brand known for delicious, versatile condiments and seasonings, is taking its craveworthy obsession to New York City with a one-of-a-kind pop-up restaurant, serving bold flavor from one of the Big Apple's tiny kitchens.
Houlihan Lokey Continues Expansion of Equity Capital Solutions Capabilities With Senior Hire — Neutral
HLI Business Wire — November 05, 2025NEW YORK--(BUSINESS WIRE)--Stephen Pollock has joined Houlihan Lokey's Capital Solutions Group as a Managing Director in Equity Capital Solutions. He is based in New York.
Will the Qualcomm stock price rise or fall after its earnings? — Negative
QCOM Invezz — November 05, 2025Qualcomm stock price has suffered a harsh reversal in the past few days as the recent excitement about its new AI chips waned. QCOM was trading at $172.85, down by 16% from its highest level this year.
Green Plains Renewable Energy (GPRE) Q3 Earnings Top Estimates — Positive
GPRE Zacks Investment Research — November 05, 2025Green Plains Renewable Energy (GPRE) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.35 per share a year ago.
McDonald's (MCD) Lags Q3 Earnings Estimates — Negative
MCD Zacks Investment Research — November 05, 2025McDonald's (MCD) came out with quarterly earnings of $3.22 per share, missing the Zacks Consensus Estimate of $3.35 per share. This compares to earnings of $3.23 per share a year ago.
Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates — Positive
CRL Zacks Investment Research — November 05, 2025Charles River Laboratories (CRL) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $2.59 per share a year ago.
Quarterly Results Push Upwork Upward, But Near-Term Pull Back Likely (Downgrade) — Neutral
UPWK Seeking Alpha — November 05, 2025Upwork Inc. delivered record Q3 results, benefiting from AI-driven demand and strong revenue, but shares have surged over 28% since the last review. UPWK is leveraging AI as an opportunity, with AI-related Gross Services Volume up 53% YOY and a growing base of AI freelancers and clients. Fundamentals remain robust, with attractive P/E and net income margins, though economic headwinds may present better entry points soon.